Acumen Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, reported a net loss of $28.8 million for the first quarter of 2025, compared to a net loss of $14.9 million in the same period of 2024. The company holds cash, cash equivalents, and marketable securities totaling $197.9 million as of March 31, 2025, which is expected to support its clinical and operational activities into early 2027. In significant business developments, Acumen has fully enrolled its ALTITUDE-AD Phase 2 study, which investigates the efficacy, safety, and tolerability of sabirnetug for treating early Alzheimer's disease. The study includes 542 participants, and the company anticipates reporting topline results in late 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.